Conference Call Participants
Paul Matteis – Stifel, Nicolaus & Company, Incorporated, Research Division
Cory Kasimov – Evercore ISI Institutional Equities, Research Division
Philip Nadeau – TD Cowen, Research Division
Brian Abrahams – RBC Capital Markets, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Corinne Jenkins – Goldman Sachs Group, Inc., Research Division
Jay Olson – Oppenheimer & Co. Inc., Research Division
Joyce Zhou – JPMorgan Chase & Co, Research Division
Mohit Bansal – Wells Fargo Securities, LLC, Research Division
Myles Minter – William Blair & Company L.L.C., Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
David Amsellem – Piper Sandler & Co., Research Division
Luke Herrmann – Robert W. Baird & Co. Incorporated, Research Division
Marc Goodman – Leerink Partners LLC, Research Division
Phoebe Tan – Jefferies LLC, Research Division
Sumant Kulkarni – Canaccord Genuity Corp., Research Division
Sean Laaman – Morgan Stanley, Research Division
Danielle Brill Bongero – Truist Securities, Inc., Research Division
Presentation
Operator
Hello, and welcome, everyone, joining today’s Neurocrine Biosciences Fourth Quarter and Fiscal Year 2025 Earnings Call. [Operator Instructions]
Please note, this call is being recorded.
[Operator Instructions]
And it is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead.
Todd Tushla
Happy Wednesday to everyone, and welcome to Neurocrine Biosciences Fourth Quarter and 2025 Year-end Earnings Call. With me today are Kyle Gano, Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; Sanjay Keswani, Chief Medical Officer; and for the first time, we are very pleased to be joined by Samir Siddhanti, Vice President of Strategy and Corporate Development.
During today’s call, we will be
